Information Provided By:
Fly News Breaks for June 11, 2019
TXMD
Jun 11, 2019 | 07:48 EDT
Cowen analyst Ken Cacciatore lowered his price target on TherapeuticsMD to $9 from $16 following its analyst day meeting. The company provided initial 2019 revenue projections for Imvexxy, Bijuva, and Annovera, which were modestly below expectations. Despite the shortfall, he still believes the products are sufficiently differentiated and the company is well capitalized so that it can reach profitability in the second half of 2021. Cacciatore maintained his Outperform rating on TherapeuticsMD shares.
News For TXMD From the Last 2 Days
There are no results for your query TXMD